Potential Biomarkers in the Sera of Breast Cancer Patients from Bahawalpur, Pakistan

Most of the approximately 90,000 cases of Breast Cancer (BC) documented annually in Pakistan are not diagnosed properly because of lack of suitable markers. We performed serum proteome expression profiling of BC and benign breast disease (BBD) patients with the aim to identify biomarkers that can be helpful for diagnosis and prognosis of the disease. Sera of patients were analyzed by one-dimensional SDS polyacrylamide gel electrophoresis (PAGE). Differentially expressed proteins were subjected to identification through LC-MS/MS analysis. In majority of the BC cases some acute phase proteins (APP) and some complement system components (C3 and C8) containing fractions were up-regulated with the exception of transthyretin (TTR) which was predominantly (68.75%) down-regulated (n = 33/48) in the sera of these patients. Varying expression patterns were observed in BBD patients and healthy controls. These differentially expressed proteins have the potential to serve as diagnostic biomarkers for BC as well as benign breast diseases.

[1]  Johan Lindberg,et al.  Correlation Network Analysis for Data Integration and Biomarker Selectionw , 2007 .

[2]  F. Bray,et al.  The changing global patterns of female breast cancer incidence and mortality , 2004, Breast Cancer Research.

[3]  André M Deelder,et al.  Biomarkers discovery by peptide and protein profiling in biological fluids based on functionalized magnetic beads purification and mass spectrometry. , 2010, Blood transfusion = Trasfusione del sangue.

[4]  A. Dulger,et al.  The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer , 2010, World journal of surgical oncology.

[5]  Helen Y Wang,et al.  Regulatory T cells and cancer. , 2007, Current opinion in immunology.

[6]  R. Bast,et al.  Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer , 2004, Cancer Research.

[7]  V Shane Pankratz,et al.  Benign breast disease and the risk of breast cancer. , 2005, The New England journal of medicine.

[8]  Quantification of Serum Proteins of Metastatic Oral Cancer Patients Using LC-MS/MS and iTRAQ Labeling. , 2008, The open proteomics journal.

[9]  T. Imanishi.  Clinical and experimental studies on the profiles of serum proteins in acute hepatic injury , 1981, Gastroenterologia Japonica.

[10]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[11]  K. Roemer,et al.  Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53 , 1998, Oncogene.

[12]  T. Tobe,et al.  Cloning and characterization of cDNA for inter-alpha-trypsin inhibitor family heavy chain-related protein (IHRP), a novel human plasma glycoprotein. , 1995, Journal of biochemistry.

[13]  Feng Gao,et al.  Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer , 2010, Proceedings of the National Academy of Sciences.

[14]  Lingyun Huang,et al.  Serum levels of variants of transthyretin down‐regulation in cholangiocarcinoma , 2008, Journal of cellular biochemistry.

[15]  A. Tall,et al.  HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. , 2008, Cell metabolism.

[16]  Heidi L. Weiss,et al.  Low Levels of Estrogen Receptor β Protein Predict Resistance to Tamoxifen Therapy in Breast Cancer , 2004, Clinical Cancer Research.

[17]  W. Schulz-Schaeffer,et al.  Proteomics approach to identify the interacting partners of cellular prion protein and characterization of Rab7a interaction in neuronal cells. , 2011, Journal of proteome research.

[18]  S. Elledge,et al.  Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. , 1992, Science.

[19]  H. Tilg,et al.  IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. , 1997, Immunology today.

[20]  Mahesh Choolani,et al.  Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. , 2007, Neoplasia.

[21]  T. Whiteside,et al.  For Breast Cancer Prognosis, Immunoglobulin Kappa Chain Surfaces to the Top , 2012, Clinical Cancer Research.

[22]  J. Lebreton,et al.  Biochemical and Molecular Roles of Nutrients Induction and Modulation of Acute-Phase Response by Protein Malnutrition in Rats : Comparative Effect of Systemic and Localized Inflammation on Interleukin-6 and Acute-Phase Protein Synthesis 1 , 2 , 1998 .

[23]  G Konecny,et al.  The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. , 2000, Cancer treatment and research.

[24]  Kym Faull,et al.  Characterization of serum biomarkers for detection of early stage ovarian cancer , 2005, Proteomics.

[25]  R. J. Mitchell,et al.  Associations between the two serum proteins haptoglobin and transferrin and leukaemia. , 1988, Human heredity.

[26]  M. Suchard,et al.  Validation of Candidate Serum Ovarian Cancer Biomarkers for Early Detection , 2007, Biomarker insights.

[27]  S. Sohail,et al.  Breast cancer in pakistan - awareness and early detection. , 2007, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[28]  S. Meri,et al.  Function and regulation of the complement system in cardiovascular diseases. , 2007, Frontiers in bioscience : a journal and virtual library.

[29]  O. Hashim,et al.  Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin , 2010, Proteome Science.

[30]  Ya Cao,et al.  Expression of immunoglobulin kappa light chain constant region in abnormal human cervical epithelial cells. , 2004, The international journal of biochemistry & cell biology.

[31]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[32]  W. Blaner,et al.  Studies on the metabolism of retinol and retinol-binding protein in transthyretin-deficient mice produced by homologous recombination. , 1995, The Journal of biological chemistry.

[33]  S. Hanash,et al.  Proteomics Approaches to Uncover the Repertoire of Circulating Biomarkers for Breast Cancer , 2002, Journal of Mammary Gland Biology and Neoplasia.

[34]  A. Cecchini,et al.  Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer , 2012, Breast Cancer Research and Treatment.

[35]  F. Sladek,et al.  Effect of dietary protein restriction on liver transcription factors. , 1996, The Biochemical journal.

[36]  Lajos Pusztai,et al.  Breast cancer biomarkers and molecular medicine , 2003, Expert review of molecular diagnostics.

[37]  K. Jung,et al.  Transferrin, C3 complement, haptoglobin, plasminogen and alpha 2-microglobulin in patients with urogenital tumors. , 1980, European urology.

[38]  Michael Oellerich,et al.  Proteins identified as targets of the acyl glucuronide metabolite of mycophenolic acid in kidney tissue from mycophenolate mofetil treated rats. , 2007, Biochimie.

[39]  C. Mathelin,et al.  Protéome et cancer du sein , 2006 .

[40]  Daniel W Chan,et al.  The clinical application of proteomics. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[41]  Xiao-Ying Meng,et al.  Classification of cancer types by measuring variants of host response proteins using SELDI serum assays , 2005, International journal of cancer.

[42]  D. Driesch,et al.  Posttranslational modifications of transthyretin are serum markers in patients with mycosis fungoides. , 2007, Neoplasia.

[43]  David E. Misek,et al.  Protein Biomarkers for the Early Detection of Breast Cancer , 2011, International journal of proteomics.

[44]  R. Shamburek,et al.  Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. , 2007, Current opinion in investigational drugs.

[45]  J. Søreide,et al.  Cytosol albumin content in operable breast cancer. Correlations to steroid hormone receptors, other prognostic factors and prognosis. , 1991, Acta oncologica.

[46]  H. Hanssen,et al.  Distribution of alpha-1-antitrypsin and haptoglobin phenotypes in bladder cancer patients. , 1987, Human heredity.

[47]  Wei Liu,et al.  Changes of transthyretin and clusterin after androgen ablation therapy and correlation with prostate cancer malignancy. , 2012, Translational oncology.

[48]  Francesco Saverio Tedesco,et al.  Complement in human diseases: Lessons from complement deficiencies. , 2009, Molecular immunology.

[49]  C. Yip,et al.  Lectin‐based electrophoretic analysis of the expression of the 35 kDa inter‐α‐trypsin inhibitor heavy chain H4 fragment in sera of patients with five different malignancies , 2008, Electrophoresis.

[50]  J. Raynes,et al.  Comparison of serum amyloid A protein and C-reactive protein concentrations in cancer and non-malignant disease. , 1983, Journal of clinical pathology.

[51]  Mitch Dowsett,et al.  Current and emerging biomarkers in breast cancer: prognosis and prediction. , 2010, Endocrine-related cancer.

[52]  S. Moshkovskii,et al.  Why do cancer cells produce serum amyloid a acute-phase protein? , 2012, Biochemistry (Moscow).

[53]  J V Castell,et al.  Interleukin-6 and the acute phase response. , 1990, The Biochemical journal.

[54]  M. Antal,et al.  Protein Status in Pancreatitis – Transthyretin Is a Sensitive Biomarker of Malnutrition in Acute and Chronic Pancreatitis , 2002, Clinical chemistry and laboratory medicine.

[55]  B. Bresnihan,et al.  Serum amyloid A in the assessment of early inflammatory arthritis. , 2000, The Journal of rheumatology.

[56]  J. Mendes,et al.  Evolution of the thyroid hormone-binding protein, transthyretin. , 2000, General and comparative endocrinology.

[57]  J. Tardif,et al.  High-density lipoprotein/apolipoprotein A-I infusion therapy , 2009, Current atherosclerosis reports.

[58]  L. Huang,et al.  A serum-derived hyaluronan-associated protein (SHAP) is the heavy chain of the inter alpha-trypsin inhibitor. , 1993, The Journal of biological chemistry.

[59]  W. Mcconathy,et al.  Serum lipids and apolipoproteins in women with breast masses , 1995, Breast Cancer Research and Treatment.

[60]  Lingyun Huang,et al.  Reduced transthyretin expression in sera of lung cancer , 2007, Cancer science.

[61]  R. Ankathil,et al.  Total hemolytic complement (CH50) and its fractions (C3 and C4) in the sera of patients with carcinoma of the oral cavity, uterine cervix, and breast , 1987, Journal of Clinical Immunology.

[62]  W. Cho,et al.  Research progress in SELDI-TOF MS and its clinical applications , 2006, Chinese Journal of Biotechnology.

[63]  G. Beckman,et al.  Haptoglobin groups and lung cancer. , 1986, Human heredity.

[64]  K. Coombes.  Analysis of mass spectrometry profiles of the serum proteome. , 2005, Clinical chemistry.

[65]  Priyadharsini Nagarajan,et al.  Evaluating Peptide Mass Fingerprinting-based Protein Identification , 2008, Genom. Proteom. Bioinform..

[66]  Jacques Ferlay,et al.  Estimates of the worldwide incidence of 25 major cancers in 1990 , 1999, International journal of cancer.

[67]  Alberto Mantovani,et al.  Macrophages, innate immunity and cancer: balance, tolerance, and diversity. , 2010, Current opinion in immunology.

[68]  Jack D Bui,et al.  Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? , 2007, Current opinion in immunology.

[69]  N. Kayani,et al.  Cancer profile of Larkana, Pakistan (2000-2002). , 2006, Asian Pacific journal of cancer prevention : APJCP.

[70]  H. Verhaegen,et al.  Increase of serum complement levels in cancer patients with progressing tumors , 1976, Cancer.

[71]  D. Mikhailidis,et al.  Multiple actions of high-density lipoprotein , 2008, Current opinion in cardiology.

[72]  J. A. Hamilton,et al.  Expression and amplification of cyclin genes in human breast cancer. , 1993, Oncogene.

[73]  J. Harvey,et al.  Breast cancer—facts and figures , 2013 .

[74]  L. Irwig,et al.  The Influence of Knowledge of Mammography Findings on the Accuracy of Breast Ultrasound in Symptomatic Women , 2005, The breast journal.

[75]  M. Molloy,et al.  Proteomics: technologies and applications. , 2002, Briefings in functional genomics & proteomics.

[76]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[77]  N G Anderson,et al.  Twenty years of two‐dimensional electrophoresis: Past, present and future , 1996, Electrophoresis.

[78]  L. Coussens,et al.  Humoral immunity, inflammation and cancer. , 2007, Current opinion in immunology.

[79]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[80]  V. Speirs,et al.  Reduced expression of oestrogen receptor β in invasive breast cancer and its re‐expression using DNA methyl transferase inhibitors in a cell line model , 2003, The Journal of pathology.

[81]  K. Chong-Kook,et al.  Identification of hemoglobin‐α and ‐β subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer , 2005, Cancer science.

[82]  Enas A. Hamed,et al.  Apoptosis, angiogenesis, inflammation, and oxidative stress: basic interactions in patients with early and metastatic breast cancer , 2012, Journal of Cancer Research and Clinical Oncology.

[83]  Jilin Li,et al.  Proteomic analysis of blood level of proteins before and after operation in patients with esophageal squamous cell carcinoma at high-incidence area in Henan Province. , 2004, World journal of gastroenterology.

[84]  J. Sampson,et al.  Immunotherapy of malignant brain tumors , 2008, Immunological reviews.

[85]  H. Nagawa,et al.  Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma , 2004, Breast Cancer Research.

[86]  J. Sehouli,et al.  Transthyretin, a biomarker for nutritional status and ovarian cancer. , 2005, Cancer research.

[87]  C. Pichard,et al.  Role of polyunsaturated fatty acids and lipid peroxidation on colorectal cancer risk and treatments , 2012, Current opinion in clinical nutrition and metabolic care.

[88]  Mitch Dowsett,et al.  Proliferation marker Ki-67 in early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  G. Mills,et al.  Lysophospholipids activate ovarian and breast cancer cells. , 1995, The Biochemical journal.

[90]  A. Akhter,et al.  A differential study of breast cancer patients in Punjab, Pakistan. , 2003, JPMA. The Journal of the Pakistan Medical Association.

[91]  H. Kölbl,et al.  The humoral immune system has a key prognostic impact in node-negative breast cancer. , 2008, Cancer research.

[92]  G. Palomaki,et al.  Reference distributions for the negative acute‐phase proteins, albumin, transferrin, and transthyretin: A comparison of a large cohort to the world's literature , 1999, Journal of clinical laboratory analysis.

[93]  J. Sodetz,et al.  Role of the human C8 subunits in complement-mediated bacterial killing: evidence that C8 gamma is not essential. , 2002, Molecular immunology.

[94]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[95]  L. Holmberg,et al.  A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors , 2012, Clinical Cancer Research.